medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2014, Number 2

<< Back Next >>

Rev Mex Patol Clin Med Lab 2014; 61 (2)

Apolipoprotein B levels in patients with Metabolic Syndrome

Querales M, Cruces ME, Mendoza C, Malvacia F, Mendoza M, Millán S

Language: Spanish
References: 38
Page: 78-83
PDF size: 170.60 Kb.


ABSTRACT

The metabolic syndrome (MS) represents a set of cardiometabolic factors in the same individual. Even knowing that the levels of apolipoprotein B (ApoB) are a powerful predictor of cardiovascular risk, the study in patients with metabolic syndrome is scarce. That is why, in this study, their concentrations were evaluated in 31 subjects with metabolic syndrome, while the same were correlated with other parameters that define the syndrome: glucose, lipid profile, blood pressure and waist circumference. 100% of patients had elevated levels of ApoB while only 12.9% had abnormalities of lipoprotein cholesterol (LDL-c) and non-HDL cholesterol. Furthermore, concentrations of ApoB were inversely correlated with intermediate and abdominal circumference (r = -0.4568, p = 0.0104). The results of this study support the inclusion of the measurement of serum ApoB levels as part of the study in clinical laboratories for better clinical and therapeutic approach to patients with metabolic syndrome.


REFERENCES

  1. Bello B, Sánchez G, Campos A, Báez E, Fernández J et al. Síndrome Metabólico: un problema de salud con múltiples definiciones. Rev Med Electrón [Internet]. 2012; 34(2) (citado: Octubre, 2013). Disponible en:http://www.revmatanzas.sld.cu/revista%20medica/ano%202012/vol2%202012/tema09.htm.

  2. Mottillo S, Filion K, Genest J, Joseph L, Pilote L, Poirier P et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010; 56: 1113-1132.

  3. Bustos P, Saez K, Gleisner A, Ulloa N, Calvo C et al. Metabolic syndrome in obese adolescents. Pediatric Diabetes. 2010; 11 (1): 55-60.

  4. 4 Hoffman R. Metabolic syndrome racial differences in adolescents. Current Diabetes Reviews. 2009; 5 (4): 259-265.

  5. Ford E, Zhao C. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. Journal of Diabetes. 2010; 2: 180–193.

  6. Beltrán H, Harhay M, Harhay M, McElligott S. Prevalence and Trends of Metabolic Syndrome in the Adult U.S. Population, 1999–2010. JACC. 2013; 62 (8): 697-703.

  7. Márquez F, Macedo G, Viramontes D, Fernández J, Salas J et al. The prevalence of metabolic syndrome in Latin America: a systematic review. Public Health Nutr. 2011; 14: 1702-1713.

  8. Escobedo J, Schargrodsky H, Champagne B, Silva H, Boissonne C et al. Prevalence of the Metabolic Syndrome in Latin America and its association with sub-clinical carotid atherosclerosis: the CARMELA cross sectional study. Cardiovascular Diabetology. 2009; 8: 52-60.

  9. Ruiz N, Espinoza M, Barrios E, Reigosa A. Factores Cardiometabólicos en una Comunidad de Valencia, Venezuela. Rev Salud Pública. 2009; 11: 1-8.

  10. Foro Dislipidemia Aterogénica. Consenso multidisciplinar sobre dislipidemia aterogénica. Clin Invest Arterioscl. 2013; 25 (2): 83-91.

  11. Núñez M, Montoya P, Pintó X. Riesgo vascular residual: Recomendaciones de la Iniciativa Española para la Reducción del Riesgo Residual. Med Clin (Barc). 2010; 135: 165-171.

  12. Davidson M. Apolipoprotein measurements: is more widespread use clinically indicated? Clin Cardiol. 2009; 32 (9): 482-486.

  13. Hermans M, Sacks F, Ahn S, Rousseau M. Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence. Cardiovascular Diabetology. 2011; 10: 20-26.

  14. Brunzell J, Davidson M, Furberg C, Goldberg R, Howard B et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008; 31: 811-822.

  15. De Abajo, F. La declaración de Helsinki VI: una revisión necesaria, pero ¿suficiente? Rev Esp Salud Pública. 2001; 75: 407-420.

  16. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. Geneva, World Health Organitation. WHO Technical Report Series, N°.854. 1993: 429-430.

  17. Pickering T, Hall J, Appel L, Falkner B, Graves J et al. Recommendation for blood pressure measurements in humans and experimental animals. Part 1: Blood Pressure measurements in humans. Hypertension. 2005; 45: 142-161.

  18. Executive summary of the Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA. 2001; 285: 2486-2497.

  19. Riediger N, Bruce S, Young T. Cardiovascular risk according to plasma apolipoprotein and lipid profiles in a Canadian First Nation. Prev Chronic Dis. 2011; 8 (1): A05.

  20. Millán J, Pintó X, Muñoz A, Zúñiga M, Rubiés-Prat J et al. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag. 2009; 5: 757-765.

  21. Dhangana R, Murphy T, Zafar A, Qadeer F, Cerezo J et al. Optimal use of Framingham risk scores to identify individuals for intensive medical risk factor modification. Circulation. 2009; 120 (suppl): S423.

  22. Benozzi S, Coniglio R. Aterosclerosis: biomarcadores plasmáticos emergentes. Acta Bioquim Clin Latinoam. 2010; 44 (3): 317-328.

  23. Koskinen J, Magnussen C, Würtz P, Soininen P, Kangas A, et al. Apolipoprotein B, oxidized low-density lipoprotein, and LDL particle size in predicting the incidence of metabolic syndrome: the Cardiovascular Risk in Young Finns study. Eur J Prev Cardiol. 2012; 19 (6): 1296-1303.

  24. Ryoo J, Park S. Association of apolipoprotein B and incidence of metabolic syndrome in Korean men: a 5-years’ follow-up study. Atherosclerosis. 2013; 226 (2): 496-501.

  25. Espinoza M, Figueira D, Cid S, Barrios E, Ruiz N et al. Caracterización fenotípica de lipoproteínas de baja densidad y su relación con el síndrome metabólico. Salus. 2012; 16 (2): 40-46.

  26. Prudente I, Castro M, Alallón W. Correlación entre las concentraciones séricas de apolipoproteína B y colesterol LDL en una muestra poblacional. Utilidad de la apolipoproteína B para valorar riesgo aterogénico. Mem Inst Investig Cienc Salud. 2006; 2 (1): 44–49.

  27. Ruiz N, Castillo V, Colina F, Espinoza M, Leal U et al. Factores de riesgo cardiovascular y perfil apolipoproteico en un grupo de adultos atendidos en un Centro Público de Salud del estado Carabobo, Venezuela. Rev Peru Med Exp Salud Publica. 2011; 28 (2): 247-255.

  28. Sniderman A, Couture P, de Graaf J. Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. Nat Rev Endocrinol. 2010; 6 (6): 335-346.

  29. Castillo I, Armas N, Dueñas A, González O, Arocha A et al. Riesgo cardiovascular según tablas de la OMS, el estudio Framingham y la razón apolipoproteína B/apolipoproteína A1. Rev Cubana Invest Biomed. 2010; 29 (4): 479-488.

  30. Boekholdt S, Arsenault B, Mora S, Pedersen T, LaRosa J et al. Association of LDL cholesterol, non–HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins. A meta-analysis. JAMA. 2012; 307 (12): 1302-1309.

  31. Harper C, Jacobson T. Using apolipoprotein B to manage dyslipidemic patients: time for a change? May. 2010; 85 (5): 440-445.

  32. The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009; 302 (18): 1993-2000.

  33. As S, Sahukar S, Murthy J, Kumar K. A study of serum apolipoprotein A1, apolipoprotein B and lipid profile in stroke. J Clin Diagn Res. 2013; 7 (7): 1303-1306.

  34. Sniderman A, Williams K, Contois J, Monroe H, McQueen M et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011; 4: 337-345.

  35. Sniderman A, Islam S, Yusuf S, McQueen M. Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. Atherosclerosis. 2012; 225 (2): 444-449.

  36. Siniawski D, Masson W, Bluro I, Sorroche P, Sscordo W et. al. Niveles plasmáticos de apolipoproteínas en una población saludable de la Argentina: implicaciones en prevención cardiovascular. Rev Argent Cardiol. 2010; 78 (2): 123-128.

  37. Mathieu P, Poirier P, Pibarot P, Lemieux I, Despres JP. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension. 2009; 53 (4): 577-584.

  38. Acosta E. Vigencia del síndrome metabólico. Acta Bioquím Clín Latinoam. 2011; 45 (3): 423-430.




2020     |     www.medigraphic.com